During the past decade, Richmond AIDS Consortium conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Richmond AIDS Consortium" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 18 trials, followed by "Glaxo Wellcome" with 3 trials sponsored, "Pfizer" with 2 trials sponsored, "Pharmacia and Upjohn" with 2 trials sponsored and "Boehringer Ingelheim" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Richmond AIDS Consortium" #1 collaborator was "Hoffmann-La Roche" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Fujisawa Pharmaceutical Co" with 1 trials as a collaborator, "Glaxo Wellcome" with 1 trials as a collaborator and "Jacobus Pharmaceutical" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Richmond AIDS Consortium" are "HIV Infections" (28 trials), "Meningitis, Cryptococcal" (3 trials), "Pneumonia, Pneumocystis Carinii" (3 trials), "Tuberculosis" (3 trials) and "Mycobacterium Avium-intracellulare Infection" (2 trials). Many other conditions were trialed in "Richmond AIDS Consortium" in a lesser frequency.

Most popular intervention types in "Richmond AIDS Consortium" are "Drug" (22 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Zidovudine" (5 trials), "Didanosine" (3 trials), "Fluconazole" (3 trials), "Amphotericin B" (2 trials) and "Clarithromycin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Richmond AIDS Consortium" are 27 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Richmond AIDS Consortium". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in Richmond AIDS Consortium, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Richmond AIDS Consortium, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 10 trials that are defined as “Not Applicable".